Prukaloprid etkileşimleri

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Amfetamin etiketi, Uyarılar ve önlemler)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (Amfetamin ve dekstroamfetamin etiketi, Uyarılar ve önlemler)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Belladonna ve afyon etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Buprenorfin etiketi, İlaç etkileşimleri)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (Buspiron etiketi, Uyarılar)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Butalbital, aspirin, kafein ve kodein etiketi, İlaç etkileşimleri)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Butalbital, parasetamol, kafein ve kodein etiketi, İlaç etkileşimleri)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Butorfanol etiketi, Önlemler)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (Dekstroamfetamin etiketi, Uyarılar)

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Desvenlafaksin etiketi, Uyarılar ve önlemler)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (Duloksetin etiketi, Uyarılar ve önlemler)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (Essitalopram etiketi, Uyarılar ve önlemler)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Fentanil etiketi, Uyarılar ve önlemler)

If concomitant use of PROZAC with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 5.2 ) (Fluoksetin etiketi, Uyarılar ve önlemler)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Fluvoksamin etiketi, Uyarılar ve önlemler)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs. (Granisetron etiketi, Uyarılar ve önlemler)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Hidrokodon etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Hidrokodon ve homatropin etiketi, İlaç etkileşimleri)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Hidrokodon ve ibuprofen etiketi, Önlemler)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (Hidrokodon ve klorfeniramin etiketi, İlaç etkileşimleri)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Hidrokodon ve parasetamol etiketi, Önlemler)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Hidromorfon etiketi, İlaç etkileşimleri)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Kodein etiketi, İlaç etkileşimleri)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Levomilnasipran etiketi, Uyarılar ve önlemler)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Levorfanol etiketi, Önlemler)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Lisdeksamfetamin etiketi, Uyarılar ve önlemler)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (Lityum etiketi, Uyarılar ve önlemler)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Metadon etiketi, Uyarılar ve önlemler)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (Metaksalon etiketi, İlaç etkileşimleri)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Metamfetamin etiketi, Uyarılar ve önlemler)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Metilen mavisi etiketi, İlaç etkileşimleri)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Milnasipran etiketi, Uyarılar ve önlemler)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (Mirtazapin etiketi, Uyarılar ve önlemler)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (Morfin etiketi, İlaç etkileşimleri)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (Oksikodon etiketi, İlaç etkileşimleri)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Oksimorfon etiketi, İlaç etkileşimleri)

If concomitant use of olanzapine and fluoxetine capsules with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 5.6 ) (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Oliseridin etiketi, İlaç etkileşimleri)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (Ondansetron etiketi, Uyarılar ve önlemler)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (Palonosetron etiketi, Uyarılar ve önlemler)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Parasetamol ve kodein etiketi, Önlemler)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Paroksetin etiketi, Uyarılar ve önlemler)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (Pentazosin ve nalokson etiketi, Önlemler)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (Prometazin ve kodein etiketi, İlaç etkileşimleri)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (Remifentanil etiketi, Uyarılar ve önlemler)

Sarı kantaronun antidepresanlarla ve diğer serotonerjik ilaçlarla birlikte alınması serotonin sendromu riskini artırır. (NCCIH, St. John's Wort)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Sertralin etiketi, Uyarılar ve önlemler)

If serotonin syndrome symptoms occur with the use of other serotonergic drugs, immediately discontinue TONMYA. (Siklobenzaprin etiketi, İlaç etkileşimleri)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Sitalopram etiketi, Uyarılar ve önlemler)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with MAOIs when used concomitantly with other serotonergic drugs. (Tranilsipromin etiketi, Uyarılar ve önlemler)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (Trazodon etiketi, Uyarılar ve önlemler)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (Venlafaksin etiketi, Uyarılar ve önlemler)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Vilazodon etiketi, Uyarılar ve önlemler)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (Vortioksetin etiketi, Uyarılar ve önlemler)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (Ziprasidon etiketi, Uyarılar ve önlemler)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (Nalbufin etiketi, İlaç etkileşimleri)

…and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Warnings… (Tramadol etiketi, İlaç etkileşimleri)

…Syndrome: The development of a potentially life-threatening serotonin syndrome has been reported with serotonin norepinephrine re-uptake inhibitors (SNRIs) and SSRIs, including NORPRAMIN, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (Desipramin etiketi, Uyarılar)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including clomipramine hydrochloride capsules, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (Klomipramin etiketi, Uyarılar)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Pamelor, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (Nortriptilin etiketi, Uyarılar)

Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (Oksikodon ve parasetamol etiketi, İlaç etkileşimleri)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including trimipramine capsules, alone, but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (Trimipramin etiketi, Uyarılar)